No Need for Metadata Here

No Need for Metadata Here

DOI: 10.3310/hta17300 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 30 Ovid MEDLINE(R) 1950 to September week 1 2010 1. exp Anticoagulants/ (159,888) 2. (anticoagulant$ or anticoagulation).mp. (69,316) 3. (anti coagulant$ or anti coagulation).mp. (1193) 4. (warfarin or acenocoumarol or coumadin or coumarin or phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or dicoumarol or dicumarol).mp. (24,778) 5. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or ly517717 or ym150 or betrixaban or idraparinux).mp. (1606) 6. or/1-5 (182,359) 7. atrial fibrillation.mp. (33,393) 8. 6 and 7 (4989) Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 27 September 2010 1. (anticoagulant$ or anticoagulation).mp. (1463) 2. (anti coagulant$ or anti coagulation).mp. (55) 3. (warfarin or acenocoumarol or coumadin or coumarin or phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or dicoumarol or dicumarol).mp. (1003) 4. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or ly517717 or ym150 or betrixaban or idraparinux).mp. (91) 5. atrial fibrillation.mp. (1255) 6. or/1-4 (2289) 7. 5 and 6 (211) EMBASE (Ovid) 1980 to September 2010 1. (anticoagulant$ or anticoagulation).mp. 2. (anti coagulant$ or anti coagulation).mp. 3. (warfarin or acenocoumarol or coumadin or coumarin or phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or dicoumarol or dicumarol).mp. 4. (phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or ly517717 or ym150 or betrixaban or idraparinux).mp. 5. exp anticoagulant agent/ 6. atrial fibrillation.mp. 7. 1 or 2 or 3 or 4 or 5 8. 6 and 7 The Cochrane Library (Cochrane Central Register of Controlled Trials) 2010 Issue 3 1. anticoagulation or anticoagulant* 2. (anti next coagulant*) or (anti next coagulation) 3. MeSH descriptor Anticoagulants explode all trees © Queen’s Printer and Controller of HMSO 2013. This work was produced by Lane et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed 133 to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. APPENDIX 2 4. warfarin or acenocoumarol or coumadin or coumarin or phenprocoumon or sintrom or sinthrome or jantoven or marevan or waran or nicoumalone or dicoumarol or dicumarol 5. phenindione or dabigatran or ximelagatran or apixaban or rivaroxaban or edoxaban or azd0837 or ly517717 or ym150 or betrixaban or idraparinux 6. (1 OR 2 OR 3 OR 4 OR 5) 7. atrial next fibrillation 8. MeSH descriptor Atrial Fibrillation explode all trees 9. (7 OR 8) 10. (6 AND 9) 134 NIHR Journals Library www.journalslibrary.nihr.ac.uk.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us